Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors.

Liao AT, Chien MB, Shenoy N, Mendel DB, McMahon G, Cherrington JM, London CA.

Blood. 2002 Jul 15;100(2):585-93. Erratum in: Blood 2002 Oct 15;100(8):2696.

2.

Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296.

Ueda S, Ikeda H, Mizuki M, Ishiko J, Matsumura I, Tanaka H, Shibayama H, Sugahara H, Takai E, Zhang X, Machii T, Kanakura Y.

Int J Hematol. 2002 Dec;76(5):427-35.

PMID:
12512837
3.

EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.

Pan J, Quintás-Cardama A, Kantarjian HM, Akin C, Manshouri T, Lamb P, Cortes JE, Tefferi A, Giles FJ, Verstovsek S.

Blood. 2007 Jan 1;109(1):315-22. Epub 2006 Aug 15.

4.

Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.

Pryer NK, Lee LB, Zadovaskaya R, Yu X, Sukbuntherng J, Cherrington JM, London CA.

Clin Cancer Res. 2003 Nov 15;9(15):5729-34.

6.

Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant.

Shivakrupa R, Bernstein A, Watring N, Linnekin D.

Cancer Res. 2003 Aug 1;63(15):4412-9.

8.
9.

Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.

London CA, Hannah AL, Zadovoskaya R, Chien MB, Kollias-Baker C, Rosenberg M, Downing S, Post G, Boucher J, Shenoy N, Mendel DB, McMahon G, Cherrington JM.

Clin Cancer Res. 2003 Jul;9(7):2755-68.

10.

SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.

Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM.

Mol Cancer Ther. 2003 May;2(5):471-8.

11.

Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.

Prenen H, Cools J, Mentens N, Folens C, Sciot R, Schöffski P, Van Oosterom A, Marynen P, Debiec-Rychter M.

Clin Cancer Res. 2006 Apr 15;12(8):2622-7.

12.

Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells.

Krystal GW, Honsawek S, Kiewlich D, Liang C, Vasile S, Sun L, McMahon G, Lipson KE.

Cancer Res. 2001 May 1;61(9):3660-8.

13.

Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region.

Chan PM, Ilangumaran S, La Rose J, Chakrabartty A, Rottapel R.

Mol Cell Biol. 2003 May;23(9):3067-78.

14.
15.

The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases.

Tatton L, Morley GM, Chopra R, Khwaja A.

J Biol Chem. 2003 Feb 14;278(7):4847-53. Epub 2002 Dec 9.

17.

SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase.

Yee KW, O'Farrell AM, Smolich BD, Cherrington JM, McMahon G, Wait CL, McGreevey LS, Griffith DJ, Heinrich MC.

Blood. 2002 Oct 15;100(8):2941-9.

18.

Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain.

Tsujimura T, Morimoto M, Hashimoto K, Moriyama Y, Kitayama H, Matsuzawa Y, Kitamura Y, Kanakura Y.

Blood. 1996 Jan 1;87(1):273-83.

19.

In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit.

Corbin AS, Demehri S, Griswold IJ, Wang Y, Metcalf CA 3rd, Sundaramoorthi R, Shakespeare WC, Snodgrass J, Wardwell S, Dalgarno D, Iuliucci J, Sawyer TK, Heinrich MC, Druker BJ, Deininger MW.

Blood. 2005 Jul 1;106(1):227-34. Epub 2005 Mar 3.

20.

Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ.

Blood. 2000 Aug 1;96(3):925-32.

Items per page

Supplemental Content

Write to the Help Desk